Join

Compare · BDX vs EMBC

BDX vs EMBC

Side-by-side comparison of Becton Dickinson and Company (BDX) and Embecta Corp. (EMBC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and EMBC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $41.65B, about 207.7x EMBC ($200.5M).
  • Over the past year, BDX is down 13.0% and EMBC is down 66.2% - BDX leads by 53.2 points.
  • BDX has been more active in the news (10 items in the past 4 weeks vs 5 for EMBC).
  • BDX has more recent analyst coverage (25 ratings vs 9 for EMBC).
PerformanceBDX-12.95%EMBC-66.20%
2025-06-09+0.00%2026-06-08
MetricBDXEMBC
Company
Becton Dickinson and Company
Embecta Corp.
Price
$150.14-0.71%
$3.35-1.03%
Market cap
$41.65B
$200.5M
1M return
-2.01%
-7.20%
1Y return
-12.95%
-66.20%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
News (4w)
10
5
Recent ratings
25
9
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

EMBC

Embecta Corp.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Latest BDX

Latest EMBC